<DOC>
	<DOCNO>NCT01855360</DOCNO>
	<brief_summary>The objective study determine whether combination bile acid TUDCA , doxycycline slow progression familial senile amyloidosis .</brief_summary>
	<brief_title>Tolerability Efficacy Combination Doxycycline TUDCA Patients With Transthyretin Amyloid Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Documented transthyretin cardiac amyloidosis biopsy stain use immunohistochemistry mass spectrometry Echocardiographic appearance leave ventricular wall thickness 13mm absence hypertensive heart disease Confirmed ATTR SSA genetic testing Age 1890 Male nonpregnant , nonlactating female Willingness return treatment center followup Prior liver transplantation liver transplantation anticipate less 6 month Alanine Transaminase and/or Aspartate Transaminase ≥2 x upper normal limit ( UNL ) Alkaline Phosphatase ≥2 x UNL Creatinine clearance &lt; 20 mL/min Any lab value opinion investigator might place subject unacceptable risk participation study History poor compliance History hypersensitivity ingredient study therapy Any investigational drug within 4 week prior study entry study Current use diflunisal therapy amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>amyloid</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>cardiac amyloidosis</keyword>
	<keyword>senile amyloidosis</keyword>
	<keyword>familial amyloidosis</keyword>
	<keyword>transthyretin amyloidosis</keyword>
</DOC>